A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer by Wolff, RF et al.
European Journal of Cancer (2015) 51, 2345–2367Ava i l ab l e a t www.sc i enced i r e c t . com
ScienceDirect
journa l homepage : www.e j cancer . comReviewA systematic review of randomised controlled trials
of radiotherapy for localised prostate cancerhttp://dx.doi.org/10.1016/j.ejca.2015.07.019
0959-8049/ 2015 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Riccall Road, Escrick, York YO19 6F
Tel.: +44 (0)1904 727987; fax: +44 (0)1904 720429.
E-mail address: robert@systematic-reviews.com (R.F. Wolﬀ).Robert F. Wolﬀ a,⇑, Steve Ryder a, Alberto Bossi b, Alberto Briganti c, Juanita Crook d,
Ann Henry e, Jeﬀrey Karnes f, Louis Potters g, Theo de Reijke h, Nelson Stone i,
Marion Burckhardt j, Steven Duﬀy a, Gillian Worthy a, Jos Kleijnen a,kaKleijnen Systematic Reviews Ltd, York, UK
bDepartment of Radiation Oncology, Gustave Roussy Institute, Villejuif, France
cDepartment of Urology, Universita` Vita-Salute San Raﬀaele, Milan, Italy
dUniversity of British Columbia, Kelowna, Canada
eSt. James’s Hospital, Leeds, UK
fMayo Clinic, Rochester, USA
gNorth Shore-LIJ Health System, Great Neck, NY, USA
hAcademic Medical Center, Amsterdam, The Netherlands
iMount Sinai, New York, USA
j Institute of Health and Nursing Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle, Germany
kCare and Public Health Research Institute (CAPHRI), Maastricht University, The Netherlands
Received 12 February 2015; received in revised form 6 July 2015; accepted 16 July 2015
Available online 5 August 2015KEYWORDS
Brachytherapy
Cryotherapy
High-intensity focused
ultrasound ablation
Prostatic neoplasms
Prostatectomy
Radiotherapy
Review
Watchful waitingAbstract Background: Prostate cancer is the second most frequently diagnosed cancer and
the sixth leading cause of cancer death in males. A systematic review of randomised controlled
trials (RCTs) of radiotherapy and other non-pharmacological management options for loca-
lised prostate cancer was undertaken.
Methods: A search of thirteen databases was carried out until March 2014. RCTs comparing
radiotherapy (brachytherapy (BT) or external beam radiotherapy (EBRT)) to other
management options i.e. radical prostatectomy (RP), active surveillance, watchful waiting,
high intensity focused ultrasound (HIFU), or cryotherapy; each alone or in combination,
e.g. with adjuvant hormone therapy (HT), were included.
Methods followed guidance by the Centre for Reviews and Dissemination and the Cochrane
Collaboration. Indirect comparisons were calculated using the Bucher method.
Results: Thirty-six randomised controlled trials (RCTs, 134 references) were included. EBRT,
BT and RP were found to be effective in the management of localised prostate cancer. WhileD, UK.
2346 R.F. Wolﬀ et al. / European Journal of Cancer 51 (2015) 2345–2367higher doses of EBRT seem to be related to favourable survival-related outcomes they might,
depending on technique, involve more adverse events, e.g. gastrointestinal and genitourinary
toxicity. Combining EBRT with hormone therapy shows a statistically signiﬁcant advantage
regarding overall survival when compared to EBRT alone (Relative risk 1.21, 95% conﬁdence
interval 1.12–1.30). Aside from mixed ﬁndings regarding urinary function, BT and radical
prostatectomy were comparable in terms of quality of life and biochemical progression-free
survival while favouring BT regarding patient satisfaction and sexual function.
There might be advantages of EBRT (with/without HT) compared to cryoablation (with/with-
out HT). No studies on HIFU were identiﬁed.
Conclusions: Based on this systematic review, there is no strong evidence to support one ther-
apy over another as EBRT, BT and RP can all be considered as effective monotherapies for
localised disease with EBRT also effective for post-operative management. All treatments
have unique adverse events proﬁles. Further large, robust RCTs which report
treatment-speciﬁc and treatment combination-speciﬁc outcomes in deﬁned prostate cancer
risk groups following established reporting standards are needed. These will strengthen the
evidence base for newer technologies, help reinforce current consensus guidelines and establish
greater standardisation across practices.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Worldwide, prostate cancer is the second most fre-
quently diagnosed cancer and the sixth leading cause
of cancer death in males, accounting for 14% (903,500)
of the total new cancer cases and 6% (258,400) of the
total cancer deaths in males in 2008 [1]. It is currently
estimated that 1 in 7 men in the USA will be diagnosed
with prostate cancer at some time in their lives (15.3% of
men, based on 2008–2010 data), with an estimated
prevalence in 2011 of 2,707,821 men living with prostate
cancer and an estimated 233,000 new cases for 2014. For
those who have the disease, chances of surviving 5 years
after diagnosis are good (98.9% based on data from
2004–2010). Nevertheless, it is estimated that 29,480
American men will die from prostate cancer in 2014
[2,3]. Aside from reducing life expectancy, prostate can-
cer is associated with reduced quality of life in terms of
decreased sexual functioning, urinary incontinence and
changes in bowel function, all of which may occur prior
to treatment and/or worsen after treatment [4].
Prostate cancer also aﬀects society as a whole
through premature death and disability as well as
resulting human and economic consequences. It has
been estimated that approximately $11.9 billion is spent
each year in the United States on prostate cancer treat-
ment, with $4.6bn, $6.2bn and $1.1bn spent on initial
treatment, continuing care and last year of life, respec-
tively [5,6]. It is clearly important to ensure that, for
those in need of treatment, expenditure is targeted so
that the right patients are in receipt of the most eﬀective
treatment at the correct time.
Current widely accepted management options include
active surveillance, watchful waiting, radical prostatec-
tomy (RP), hormone therapy (HT), radiotherapy,
(i.e. external beam radiotherapy (EBRT) orbrachytherapy (BT)) and chemotherapy. These
approaches are applied individually, sequentially or in
combination. High intensity focused ultrasound
(HIFU) and cryotherapy are also used but to a lesser
degree [7].
However, there is a lack of systematic reviews of ran-
domised controlled trials assessing these options for
prostate cancer, i.e. RP, radiotherapy (EBRT and BT),
HIFU and cryotherapy.
In this systematic review, we aim to assess the eﬃcacy
[8] and adverse events associated with radiotherapy
(EBRT and/or BT) compared with other
non-pharmacological management options in patients
with localised prostate cancer.
2. Methods
The systematic review process followed published
guidelines [9,10].
2.1. Inclusion criteria
Our review was focused on non-pharmacological
interventions. Pharmacological management of patients
was only considered if it was an adjunct to main treat-
ment. Published and unpublished randomised controlled
trials were included when they reported on adult men
(>18 years) with prostate cancer, treated with any
form of radiotherapy (EBRT and/or BT), alone or in
combination with HT or RP, in comparison to other
relevant management options, i.e. RP, active surveillance,
watchful waiting, HIFU and cryotherapy. Outcomes
considered relevant for our review included mortality
outcomes (overall survival, disease-speciﬁc survival),
progression outcomes (clinical, biochemical and mixed
progression-free survival), adverse events (AE; including
R.F. Wolﬀ et al. / European Journal of Cancer 51 (2015) 2345–2367 2347genitourinary and gastrointestinal toxicities and sexual
functioning), patient satisfaction, treatment failure
(TF) and quality of life (QoL). The main outcome was
overall survival (OS).2.2. Literature search
Searches were undertaken to identify all relevant ran-
domised controlled trials (RCTs), regardless of language
or publication status (published, unpublished, in press
and in progress). The following databases were searched
up to February 2014: MEDLINE, MEDLINE
In-Process Citations and Daily Updates, EMBASE (all
via OvidSP) and Cochrane Central Register of
Controlled Trials (CENTRAL). In addition, a search
of PubMed was conducted in March 2014. The search
strategies (keywords) were developed speciﬁcally for
each database. Appendix 1 presents the search strategy
developed to search MEDLINE.
Additional reference checking in retrieved articles and
systematic reviews was undertaken and supplementary
searches for secondary publications were conducted:
Cochrane Database of Systematic Reviews (CDSR),
Database of Abstracts of Reviews or Eﬀects (DARE),
Health Technology Assessment (HTA) database (via
CRD website), International Prospective Register of
Systematic Reviews (PROSPERO), National Institute
for Health and Care Excellence (NICE) guidance,
Guidelines International Network (GIN), National
Institute for Health Research (NIHR) Health
Technology Assessment (HTA) Programme and
National Guidelines Clearinghouse (NGC).2.3. Methods of study selection, quality assessment and
data extraction
Two reviewers independently inspected the titles and
abstracts identiﬁed by the search. For potentially rele-
vant articles, or in cases of disagreement, the full article
was obtained, independently inspected and pre-speciﬁed
inclusion criteria applied.
For each study, data were extracted by one reviewer
and checked for accuracy by a second reviewer. A qual-
ity assessment based on the methods described in the
Cochrane Handbook was performed [11]. Study charac-
teristics and quality were presented in tables. Where
details on the risk group (i.e. D’Amico classiﬁcation)
were missing, a surrogate was created which was based
on the reported baseline characteristics of included
patients. The choice of risk stratiﬁcation system is con-
sidered in the discussion section. D’Amico classiﬁed
prostate cancer patients into 3 groups: low-risk
(prostate-speciﬁc antigen [PSA] < 10 ng/ml and clinical
stage T1c-T2a and Gleason score 6 6), intermediate risk
(PSAP 10 ng/ml, but 6 20 ng/mL or clinical stage T2b
or Gleason score = 7) and high-risk (PSA > 20 ng/ml orclinical stageP T2c or Gleason scoreP 8) [12]. Three
pre-speciﬁed categories were agreed with clinical experts
following consideration of the literature and used to
allow the comparison of diﬀerent dosages of EBRT as
monotherapy: low dose (<75 Gy), intermediate dose
(75–78 Gy), high dose (P78 Gy).
Any disagreement during data extraction was
resolved through discussion. Abstracts were also
included where full manuscripts were unavailable, in line
with current guidance [9,10].2.4. Study analyses
Tables were used to present relevant results for all
studies. All ‘head-to-head’ comparisons of comparator
treatments were performed in line with the Cochrane
Handbook [9]. Pooled eﬀect sizes (relative risks (RR))
and 95% conﬁdence intervals (95%-CIs) using random
eﬀects (inverse–variance, I–V) methods were only
reported where trials were considered to be clinically
and statistically homogeneous.3. Results
Literature searches yielded 25,867 references.
Additionally, searches were undertaken to identify rele-
vant systematic reviews, technology appraisals, guidance
and guidelines. These additional searches, aimed to
identify supplementary primary studies, retrieved a total
number of 826 hits. After removing 9,143 duplicates, a
total of 17,550 references were available for screening
(see Fig. 1).
Titles and abstracts were screened and 492 potentially
relevant papers ordered as full texts. Of these, 134 refer-
ences (relating to 36 individual studies) were included. A
list of excluded studies is available on request.3.1. Characteristics and risk of bias of included studies
Nearly all of the included studies have been con-
ducted in Europe or North America, (34 out of 36)
and two studies were carried out in Australia and
New Zealand as well as China, respectively. On aver-
age, the 36 studies included 345 patients (median 212,
total 11,731; two abstracts did not report patient
numbers).
As detailed in Table 2, few studies reported patient
risk stratiﬁcation and those that did used a variety of
classiﬁcations. Five studies [46,53,68,83,159] (including
one with follow-up < 5 years) based risk stratiﬁcation
on the D’Amico classiﬁcation (see Table 1); in one study
[49] patients were stratiﬁed according to risk as deﬁned
by the National Comprehensive Cancer Network
(NCCN); another two studies [96,82] (including one
small study n < 50 patients) used the Partin classiﬁcation
while Holmberg et al. [146] deﬁned low risk patients
Fig. 1. Flow diagram of study searches and inclusion based on PRISMA.
2348 R.F. Wolﬀ et al. / European Journal of Cancer 51 (2015) 2345–2367based on Gleason score and WHO grade. In order to
allow a more transparent way of comparing the risk
grouping of included patients, a D’Amico surrogate
was extracted based on the baseline characteristics
reported by each study (see Table 1). Two studies
included patients stratiﬁed to a single risk group ([14]
(small study) [83]). The other studies assigned patients
to two (n = 10) or three risk groups (n = 22), while
two studies provided insuﬃcient baseline data which
prevented assignment of their patients to risk groups
[157,123] (one study: unknown size and follow-up).
None of the studies fulﬁlled all pre-speciﬁed quality
criteria [11]. Common sources for potential risk of bias
included missing or insuﬃcient details on randomisation
procedure, allocation concealment and the lack of blind-
ing of patients, physicians and outcome assessors.
3.2. Summary of direct comparisons
Key survival-related ﬁndings for each treatment are
presented in Table 2. Relative eﬀects are grouped as
‘greater than’ (i.e. statistically signiﬁcant diﬀerence
(p 6 0.05) in favour of A), ‘no signiﬁcant diﬀerence’
(p > 0.05) and ‘worse than’ (i.e. statistically signiﬁcant
diﬀerence (p 6 0.05) in favour of B; see columns). A full
version of the table, including all assessed outcomes, is
available as an online Appendix.These results are also presented in a network diagram
showing the survival-related relative eﬀects of all
included studies for each identiﬁed comparison (see
Fig. 2). Endpoints for which no statistically signiﬁcant
diﬀerences were reported are represented by the grey
double lines. In contrast, endpoints for which a statisti-
cally signiﬁcant eﬀect was found are represented by the
coloured lines where the arrow points to the treatment
with the higher relative eﬀect. The numbers of studies
reporting on each outcome are given in brackets while
letters refer to the risk grade of patients included in
the studies (D’Amico surrogate). A full version of the
network is available as an online Appendix. Outcomes
relevant to mortality and/or disease progression are
highlighted in bold.
3.3. Summary of pooled estimates
For some comparisons of overall survival, available
data allowed pooling. Comparisons of EBRT (low dose)
with: (1) EBRT (low dose) combined with HT; (2)
EBRT (low dose) + BT, i.e. combined dose escalation;
as well as (3) EBRT (high dose) were all possible.
Furthermore, pooling was possible for two studies
comparing RP with watchful waiting and RP with RP
followed by EBRT. Only one of these comparisons
showed a statistically signiﬁcant advantage, as shown
Table 1
Summary of characteristics of included studies.
Study Participants Risk
of
bias*
D’Amico
surrogate
Intervention Comparison Extracted outcome
Brachytherapy vs. radical prostatectomy
Crook [14–18]
Canada,
09/2002–07/2005
SPIRIT
n = 34
Stage: T1c/T2a
PSA at baseline (ng/ml): 610
Gleason score: 66
Age: 60 years (entire cohort)
TRUS volume 6 60 cm3
?/?/?/
?/?/?
Low risk Brachytherapy (no further
details)
RP Bowel function (EPIC),
patient satisfaction
(EPIC), sexual function
(EPIC), urinary function
(EPIC)
Giberti [19]
Italy, 05/1999–10/2002
n = 174
Stage: cT1c-cT2a
PSA at baseline (ng/ml, mean): 7.8 (RP), 7.5
(brachytherapy)
Gleason score: 5.8 (mean)
Age: 65 years (mean)
/?/
?/ /
?/
Low-
intermediate
risk
Brachytherapy (no further
details)
RP Bowel function
(EORTC-QLQ-PR25),
bPFS, QoL (EORTC-
QLQ-C30), sexual
function (IIEF), urinary
function (EORTC-QLQ-
PR25)
Brachytherapy vs. Brachytherapy + hormone therapy
Cui [41]
China, NR
(Abstract only)
n = 165
Stage: T1c-T3b
PSA at baseline (ng/ml, median): 26.5
Gleason score: not reported
Age: 79 years (median)
?/?/?/
?/ /
low–high risk Brachytherapy (I-125) Brachytherapy (I-125) after
3 month neoadjuvant HT
(no further details)
bPFS
Cryoablation vs. external beam radiation therapy (low dose)
Al-Zahrani [42–45]
Canada, 1999–2002
(Abstract only)
n = 62
Stage: cT2c-cT3b
PSA at baseline (ng/ml): <25
Gleason score: not reported
Age: not reported
Negative metastatic evaluation on CT and bone scan
?/?/?/
?/?/
Intermediate-
high risk
EBRT (66 Gy in 33
fractions)
Cryoablation bPFS, DSS, OS
Donnelly [46,47]
Canada,
12/1997–02/2003
n = 231
Stage: pT2-pT3N0M0
PSA at baseline (ng/ml, median): 8.1 (cryoablation),
9.0 (EBRT)
Gleason score: 35% 66, 55% 7, 10% 8–10
Age: 69 years (median)
Risk (D’Amico): 8% low, 26% intermediate, 66% high
Prostate volume 6 60 cm3
?/?/?/
?/ /
Low–high
risk
EBRT (68 Gy-73.5 Gy) Cryoablation Bowel function (PCI),
DSS, mPFS, OS, QoL
(EORTC-QLQ-C30),
sexual function
(intercourse at
36 months), urinary
function (PCI)
External beam radiation therapy (low dose) vs. external beam radiation therapy (low dose) + brachytherapy
Hoskin [48–52]
UK, 12/1997–08/2005
n = 218
Stage: T1-T3M0
PSA at baseline (ng/ml): 33% <10, 41% 10–19.9, 26%
P20
Gleason score: 42% 66, 42% 7, 16% 8–10
Age: 68.9 years (mean)
Risk (NCCN): 4% low, 42% intermediate, 54% high
?/?/
/ /
/
Low–high
risk
EBRT (55 Gy in
20 fractions)
EBRT (35.75 Gy in
13 fractions) + HDR-BT
(2 8.5 Gy)
Bowel function
(modiﬁed Dische Scales),
bPFS, mPFS, OS, QoL
(FACT-P), urinary
function (modiﬁed
Dische Scales)
(continued on next page)
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Table 1 (continued)
Study Participants Risk
of
bias*
D’Amico
surrogate
Intervention Comparison Extracted outcome
Sathya [53]
Canada,
05/1992–12/1997
n = 104
Stage: T2-T3N0M0 (TNM 1992)
PSA at baseline (ng/ml): 37% <10, 28% 10–19.9, 35%
P20
Gleason score: 36% 66, 49% 7, 15% 8–10
Age: 65 years (mean)
Risk (D’Amico): 40% intermediate, 60% high
?/ /
?/ /
/
Low–high
risk
EBRT (40 Gy in 20
fractions) + BT (iridium
implant, 35 Gy)
EBRT (66 Gy in
33 fractions)
mPFS, OS, toxicity
Zapatero-Ortuno [54]
Spain, NR
(Abstract only)
n = 30
Intermediate risk localised disease.
Stage: T1c-T2c
PSA at baseline (ng/ml, median): 9.76
Gleason score: 57% 66, 43% 7
Age: 68.57 years (mean)
?/?/?/
?/?/?
Low–high
risk
3DCR/EBRT
(46 Gy) + brachytherapy
boost with LDR-BT of
108 Gy)
3DCR/EBRT (76 Gy) bPFS, OS, sexual
function (IIEF), toxicity
External beam radiation therapy (low dose) vs. external beam radiation therapy (low dose) + hormone therapy
Bolla [55–59]
European MC,
05/1987–10/1995
EORTC trial 22863
n = 401
Stage: T1–T4
PSA at baseline (ng/ml, median): 6% 64, 11% 4.1–10,
16% 10.1–20, 24% 20.1–40, 34% >40, 9% unknown
Gleason score: 6% 2–4, 22% 5–6, 34% 7–10, 38%
unknown
Age: 71 years (median)
WHO performance status 0–2
/ /
/ /
/
Low–high
risk
EBRT (70 Gy in 7 weeks) EBRT (70 Gy in
7 weeks) + adjuvant HT
AE, bPFS, DSS, OS
D’Amico [60–62]
USA, MC,
12/1995–04/2001
n = 206
Stage: cT1b–cT2b (AJCC 1992)
PSA at baseline (ng/ml, median): 11
Gleason score: 28% 5–6, 35% 3 + 4, 23% 4 + 3, 14%
8–10
Age: 73 years (median)
/?/
/ /
/
Low–high
risk
EBRT (70.35 Gy in
36 fractions)
EBRT (70.35 Gy in
36 fractions) + 6 month
HT
DSS, OS, Toxicity
Denham [63–67]
Australia and New
Zealand MC,
06/1996–02/2000
TROG 96.01
n = 802
Stage: T2b–T4
PSA at baseline (ng/ml): 4% <4, 24%P 4 and <10,
34% P10 and <20, 30% P20 and <50, 7% P50 and
<100, 1% P100
Gleason score: 44% 2–6, 38% 7, 17% 8–10, 1% missing
Age: 68 years (median)
/?/
/ /
/
Intermediate-
high risk
EBRT (66 Gy in 33
fractions)
(1) EBRT (66 Gy in 33
fractions) + 3 months
neoadjuvant HT
(2) EBRT (66 Gy in 33
fractions) + 6 months
neoadjuvant HT
bPFS, cPFS, DSS, OS,
TF
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Jones [68–72]
USA MC,
10/1994–04/2001
RTOG 94–08
n = 1979
Stage: T1b–T2b (AJCC 1992)
PSA at baseline (ng/ml): 11% <4, 89% 4–20
Gleason score: 62% 2–6, 27% 7, 9% 8–10, 2%
unknown
Age: 71 years (median)
Risk (D’Amico): 35% low, 54% intermediate, 11%
high
/?/
?/?/
/
Low–high
risk
EBRT (66.6 Gy in
37 fractions)
EBRT (66 Gy in
37 fractions) after 2 months
neoadjuvant HT and
2 months adjuvant HT
bPFS, cPFS, DSS, OS,
sexual function
Laverdie`re [73]
Canada, 1991–1994
n = 120
Stage: T2a–T3c
PSA at baseline (ng/ml): 14% <4, 40% 4–10, 23% 10–
20, 23% >20
Gleason score: 42% 63, 42% 4–6, 16% P7
Age: 70 years (mean)
?/?/?/
?/ /
Low–high
risk
EBRT (64 Gy in
32 fractions)
(1) 3 months neoadjuvant
HT + EBRT (64 Gy in
32 fractions)
(2) 3 months neoadjuvant
HT + EBRT (64 Gy in
32 fractions) + 6 months
HT
bPFS, cPFS
Pilepich [74–78]
USA MC,
04/1987–06/1991
RTOG 86–10
n = 456
Stage: T2–T4
PSA at baseline (ng/ml, median): 22.6 (EBRT + HT),
33.8 (EBRT)
Gleason score: 15% 2–5, 56% 6–7, 28% 8–10, 1%
missing
Age: 71 years
?/?/?/
?/ /
Low–high
risk
EBRT (65–70 Gy in daily
doses of 1.8–2.0 Gy)
EBRT (65–70 Gy in daily
doses of 1.8–
2.0 Gy) + neoadjuvant HT
bPFS, cPFS, DSS, OS,
TF
Zagars [79,80]USA,
11/1967–12/1973
n = 78
Stage: not reported
PSA at baseline: not reported
Gleason score: not reported
Age: 64 years (mean/median)
?/?/?/
?/ /
Low–high
risk
EBRT (70 Gy in
35 fractions)
EBRT (70 Gy in
35 fractions) + HT
(oestrogens)
DSS, OS
External beam radiation therapy (low dose) vs. external beam radiation therapy (low–high dose)
Spagnoletti [81,82]
Italy, 09/2008–07/2009
(Abstract only)
n = 40
Stage: cT1-T2N0M0
PSA at baseline: not reported
Gleason score: not reported
Risk: intermediate (Partin classiﬁcation)
?/?/?/
?/ /
Low-
intermediate
risk
CFRT (72–78 Gy in 36–39
fractions)
HFRT (64.8–70.2 Gy in
24–26 fractions)
Toxicity
External beam radiation therapy (low–high dose) vs. external beam radiation therapy (low–high dose) + hormone therapy
Mok [83]
Canada, 1999–2006
(Abstract only)
n = 243
Risk (D’Amico): (T1–T2, Gleason score 7,
PSA < 20 ng/ml; T1-T2, Gleason score 6 6, PSA 10–
20 ng/ml)
Age: not reported
?/?/?/
?/ /
Intermediate
risk
EBRT (75.6 or 79.8 Gy in
42 fractions)
EBRT (75.6 or 79.8 Gy in
42 fractions)+ 3
neoadjuvant HT
bPFS, toxicity
External beam radiation therapy (low dose) vs. external beam radiation therapy (intermediate dose)
Norkus [84]
Lithuania,
01/2010–05/2012
n = 124
Stage: 19% < T2c, 81%P T2c
PSA at baseline (ng/ml): 78% 6 20, 22% > 20
Gleason score: 91% 6 7, 9% > 7
Age: 65 years (median)
/?/
/ /
/
Low–high
risk
CFRT (76 Gy in
38 fractions)
HFRT (63 Gy in
20 fractions)
QoL, toxicity, urinary
function
(continued on next page)
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Table 1 (continued)
Study Participants Risk
of
bias*
D’Amico
surrogate
Intervention Comparison Extracted outcome
External beam radiation therapy (low dose) vs. external beam radiation therapy (high dose)
Aluwini [85]
The Netherlands MC,
04/2007–01/2011
(Abstract only)
n = 820
Stage: “localised prostate cancer”
PSA at baseline (ng/ml): not reported
Gleason score: not reported
Age: not reported
?/?/?/
?/ /
Low–high
risk
CFRT (78 Gy in 39
fractions)
HFRT (64.6 Gy in
19 fractions)
Toxicity
Arcangeli [86–92]
Italy, 01/2003–12/2007
n = 114
Stage: T2c-T4
PSA at baseline (ng/ml, mean/median): 19/13
(CFRT); 26/16 (HFRT)
Gleason score: 49% 6 3 + 4; 51%P 4 + 3
Age: 75 years (median)
?/?/?/
?/ /
Intermediate-
high risk
CFRT (80 Gy in
40 fractions) after 9 months
HT
HFRT (62 Gy in
20 fractions) after 9 months
HT
bPFS, cPFS, Toxicity
Beckendorf [93–95]
France MC,
09/1999–02/2002
GETUG-06
n = 306
Stage: T1–T3a (UICC 1997)
PSA at baseline (ng/ml): 39% <10, 45% 10 620, 16%
>20
Gleason score: 63% <7, 37% P7
Age: 67 years (mean)
?/?/?/
?/ /
Low–high
risk
EBRT (46 Gy in 23
fractions + 24 Gy = 70 Gy)
EBRT (46 Gy in 23
fractions + 34 Gy = 80 Gy)
AE, bPFS, DSS, OS,
QoL, sexual function,
toxicity
Peeters [96–104]
The Netherlands MC,
06/1997–02/2003
CKTO 96–10
n = 664
Stage: T1–T4
PSA at baseline: 7% 64, 32% 4–10, 38% 10–20, 23%
20–60
Gleason score: 30% 2–4, 55% 5–7, 15% 8–10
Age: 68.7 years (mean)
Risk: low–high (Partin classiﬁcation)
?/?/?/
?/ /
Low–high
risk
EBRT (68 Gy in
34 fractions, 22% of
patients with neoadjuvant
HT)
EBRT (78 Gy in
39 fractions, 21% of
patients with neoadjuvant
HT)
bPFS, cPFS, OS, QoL,
TF, toxicity, urinary
function
Pollack [105–113]
USA, 1993–1998
n = 301
Stage: T1–3NxN0M0
PSA at baseline (ng/ml): 11% 64; 54% 4–10; 35% >10
Gleason score: 50% 2–6, 33% 7, 17% 8–10
Age: not reported
?/?/?/
?/ /
Low–high
risk
EBRT (78 Gy;
conventional 46 Gy in
23 fractions + 32 Gy
3DCR boost)
EBRT (70 Gy in
35 fractions)
bPFS, complications,
cPFS, QoL, OS, toxicity
Zietman [114–117]
USA MC,
01/1996–12/1999
n = 393
Stage: T1b–T2b (AJCC 1992)
PSA at baseline (ng/ml): 11% <4, 74%, 4–10, 15% 10–
15
Gleason score: 75% 2–6, 15% 7, 9% 8–10, 1%
unknown
Age: 67 years (median)
/ /
?/?/
/
Low-
intermediate
risk
EBRT (70.2 Gy in 1.8 Gy
fractions)
EBRT (79.2 Gy in 1.8 Gy
fractions)
bPFS, cPFS, OS, QoL,
toxicity
2352
R
.F
.
W
o
lﬀ
et
a
l./E
u
ro
p
ea
n
J
o
u
rn
a
l
o
f
C
a
n
cer
5
1
(
2
0
1
5
)
2
3
4
5
–
2
3
6
7
External beam radiation therapy (low dose) vs. radical prostatectomy
Paulson [118,119]
USA, NR
n = 90
Stage: T1-T2N0M0 (clinical stage A2 or B)
PSA at baseline: not reported
Gleason score: not reported
Age: not reported
Normal prostatic acid phosphatase levels, negative
isotopic bone scans, no pelvic nodal extension
?/?/?/
?/?/
Low-
intermediate
risk
RP EBRT (no further details) TF
External beam radiation therapy (low dose) vs. watchful waiting
Fransson [120–122]
Sweden MC, 1986–1996
UMEA˚ 1
n = 72
Stage: T1b–T2, G1–G2, N0, M0
PSA at baseline (ng/ml): 38% < 10, 18% 10–19.9,
44%P 20
Gleason score: not reported
Age: 72 years (mean)
?/?/?/
?/ /
Low–high
risk
EBRT (64–68 Gy in 32
fractions)
WW Bowel function (PCSS),
QoL (QLQ-C30), sexual
function (PCSS), urinary
function (PCSS)
External beam radiation therapy (unclear dose) vs. external beam radiation therapy (unclear dose) + hormone therapy
Porter [123]
Canada, NR
(Abstract only)
No information available (Paper unobtainable) ?/?/?/
?/?/?
Not
estimable
EBRT (no further
information)
EBRT + neoadjuvant HT
(no further information)
No information available
External beam radiation therapy (unclear dose) vs. radical prostatectomy
Stasi [124]
Italy, 01/1997–09/2001
(Abstract only)
n = 137
“Clinically localised” prostate cancer (no further
information)
?/?/?/
?/ /
Low–high
risk
EBRT (no further details) RP Bowel function, bPFS,
cPFS, DSS, sexual
function,
urinary function
External beam radiation therapy (unclear dose) + brachytherapy vs. external beam radiation therapy (unclear dose) + brachytherapy + hormone therapy
Garcı´a Blanco [125]
Spain, 01/2007–11/2008
(Abstract only)
n = 62
“Intermediate to high risk”
No further information
?/?/?/
?/ /
Intermediate-
high
EBRT + HDR-BT (no
further information)
EBRT + HDR-BT + HT
(no further information)
bPFS, cPFS, toxicity
Radical prostatectomy vs. radical prostatectomy + EBRT
Bolla [126–133]
European MC,
11/1992–12/2001
EORTC trial 22911
n = 1005
Stage: cT0–cT3N0 (UICC 1989)
PSA at baseline (ng/ml, median): 12.4
Gleason score: not reportedvAge: 675 years
Untreated. WHO performance status 0–2
/?/
?/?/
/
Low–high
risk
RP RP + EBRT (60 Gy in
30 fractions)
AE, bPFS, DSS, mPFS,
OS, toxicity, urinary
function (pad test)
Thompson [134–137]
Canada, USA, MC,
08/1988–01/1997
n = 425
Stage: pT3N0M0
PSA at baseline (ng/ml): 50% < 10, 50%P 10
Gleason score: 50% 6 6, 36% 7, 13% 8–10
Age: 65 years (median)
RP 16 months prior to study. Negative bone scan.
/?/
/ /
/
Intermediate-
high risk
RP RP + EBRT (60–64 Gy in
30–32 fractions)
AE, bPFS, cPFS, OS,
urinary function
(continued on next page)
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Table 1 (continued)
Study Participants Risk
of
bias*
D’Amico
surrogate
Intervention Comparison Extracted outcome
Wiegel [138–141]
Germany MC,
04/1997–09/2004
ARO 96–02/AUO
AP 09/95
n = 307
Stage: pT3-pT4N0 (IUAC 1992)
PSA at baseline (ng/ml, median): 10.4
Gleason score: 32% 66, 54% 7, 14% 8–9
Age: 64 years (median)
WHO performance status 0–1.
/?/
?/?/
/
Intermediate-
high risk
RP RP + EBRT (60 Gy in
30 fractions)
mPFS, OS
Radical prostatectomy vs. watchful waiting
Holmberg [142–153]
Finland, Iceland,
Sweden, MC,
01/1989–02/1999
SPCG-4
n = 695
Stage: T0c/d-2 (IUAC 1978/1987)
PSA at baseline (ng/ml): <50
Gleason score: not reported
Age: 64 years (mean)
Life expectance > 10 years. Untreated. Negative bone
scan.
Risk (Gleason/WHO): 38% low, no further details
/?/
?/ /
/
Low–high
risk
RP WW cPFS, DSS, OS, sexual
function, urinary function
Madsen 1988 [154–156]
USA, 05/1967–03/1975
n = 142
Stage: T0-T2 (stage I and II adenocarcinoma of
prostate)
PSA at baseline: not reported
Gleason score: 87% 6 6, 13% 7–10
Age (median): 67 years (stage I), 61 years (stage II)
?/?/?/
?/ /
Low–high
risk
RP WW OS
Norlen [157]
Sweden, NR
(Abstract only)
No information available ?/?/?/
?/?/?
Not
estimable
RP WW No information available
Wilt [158–167]
USA MC,
11/1994–01/2002
Wilt 2012
n = 731
Stage: T1a-T2cNxM0
PSA at baseline (ng/ml, mean): 10.2
Gleason score: 74% 66, 19% 7, 7% 8–10
Age: 66.9 years (mean)
Risk (D’Amico): 42% low, 36% intermediate, 22%
high
/?/
?/?/
/
Low–high
risk
RP WW Bowel function, cPFS,
DSS, OS, QoL, sexual
function, urinary function
*Risk of bias items [Cochrane Handbook]: Randomisation; Allocation concealment; Patient/personnel blinding; Outcome assessor blinding; Incomplete outcome reporting; Selective outcome reporting.
= low risk of bias; = high risk of bias; ? = unclear of bias; 3DCR = Three-Dimensional Conformal Radiotherapy; AE = Adverse event; bPFS = Biochemical progression-free survival;
BT = Brachytherapy; CFRT = Conventionally fractionated radiotherapy; cPFS = Clinical progression-free survival; CT = Computer tomography; DSS = Disease-speciﬁc survival; EBRT = External
Beam Radiotherapy; EORTC = European Organization for Research and Treatment of Cancer; EPIC = Expanded Prostate Cancer Index Composite; FACT-P = Functional Assessment of Cancer
Therapy speciﬁc for prostate cancer; GETUG = Groupe d’Etude des Tumeurs Uro-Ge´nitales; Gy = Gray (SI unit of absorbed radiation); HDR = High-dose radiation; HFRT = Hypofractionated
radiotherapy; HT = Hormone therapy; IIEF = International Index of Erectile Function; IPSS = International Prostate Symptom Score; IUAC = International union against cancer;
MC =Multicentre; ml = Millilitre; mPFS =Mixed (biochemical and clinical) progression-free survival; months = Months; NCCN = National Comprehensive Cancer Network; ng = Nanogram;
NR = Not reported; OS = Overall survival; PCI = Prostate Cancer Index; PCSS = Prostate Cancer Symptom Scale; PR25 = Prostate-speciﬁc module of QLQ-C30; PSA = Prostate-Speciﬁc Antigen;
QLQ-C30 = EORTC Quality of Life Questionnaire 30-item cancer-speciﬁc module; QoL = Quality of life; RP = Radical prostatectomy; SPCG-4 = Scandinavian Prostate Cancer Group study number
4; SPIRIT = Surgical Prostatectomy versus Interstitial Radiotherapy Intervention Trial; TF = Treatment failure; TROG = Trans-Tasman Radiation Oncology Group; UICC = Union for
International Cancer Control; UK = United Kingdom; USA = United States of America; WHO =World Health Organization; WW =Watchful Waiting.
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Table 2
Key survival-related ﬁndings by comparator. (Please note that a full version of this table is available as an online Appendix.)
Intervention Relative eﬀect
Eﬀect greater than No signiﬁcant diﬀerence Eﬀect worse than
Brachytherapy RP: bPFS, (Giberti, 2009, n = 174, low-intermediate
risk)
Cryoablation EBRT (low dose): mPFS (36 months, diﬀerence 3.9%,
95%-CI 5.3 to 13.2) (Donnelly, 2010, n = 231, low–
high risk); DSS, OS (Al-Zahrani, 2011; Donnelly, 2010),
n = 293, low–high risk)
EBRT (low dose): bPFS (8 yrs: 17.4% vs. 59.1%,
p = 0.01) (Al-Zahrani, 2011, n = 62, intermediate-high
risk)
EBRT (low dose) Cryoablation: bPFS (8 yrs: 17.4% vs. 59.1%, p = 0.01)
(Al-Zahrani 2011, n = 62, intermediate-high risk)
EBRT (high dose, CFRT) [vs. EBRT (low dose,
HFRT)]: bPFS (79% vs. 87%, p = 0.035)
(Arcangeli, 2010, n = 114, intermediate-high risk)
Cryoablation: mPFS (36 months, diﬀerence 3.9%, 95%-
CI 5.3 to 13.2) (Donnelly 2010, n = 231, low–high
risk); DSS, OS (2 studies (Al-Zahrani, 2011; Donnelly,
2010), n = 293, low–high risk)
EBRT (low dose) ± BT: bPFS (n = 0 after mean FUP
22.7 months, PSA after 17.5 months: 0.68 ng/ml vs.
0.88 ng/ml, p = 0.44) (Zapatero-Ortuno, 2010, n = 30,
low-intermediate risk); OS (n = 0 after mean FUP
22.7 months; HR 1.36, 95%-CI 0.50–3.65, p = 0.54;
10 yrs, p = 0.2) (3 studies (Hoskin, 2007; Sathya, 2005;
Zapatero-Ortuno, 2010), n = 352, low–high risk)
EBRT (low dose) ±HT: bPFS (2 yrs) (Laverdie`re,
1997, n = 120, low–high risk); OS (10 yrs, 8.7 vs. 7.3 yrs,
p = 0.12; 15 yrs, no signiﬁcant diﬀerence) (2 studies
(Pilepich, 1995; Zagars, 1988), n = 534, low–high risk)
EBRT (high dose): cPFS (clinical failure, HR 0.89,
95%-CI 0.69–1.15) (Peeters, 2006, n = 664, low–high
risk); DSS (54 months, p = 0.61; 110 months, HR 0.96,
95%-CI 0.63–1.45) (2 studies (Beckendorf, 2004;
Peeters, 2006), n = 968, low–high risk); bPFS (5 yrs,
Phoenix, 23.5 vs. 32%; 10 yrs, Phoenix, p = 0.001)
(2 studies (Beckendorf, 2004; Zietman, 2005), n = 699,
low–high risk); OS (54 months, p = 0.52; 110 months,
HR 0.99, 95%-CI 0.75–1.3; 8 yrs, no overall diﬀerence)
(4 studies (Beckendorf, 2004; Peeters, 2006; Pollack,
2000; Zietman), n = 1662, low–high risk)
EBRT (low dose) ± BT: bPFS (Hoskin, 2007, n = 218,
low–high risk); mPFS (HR 0.42, 95%–CI 0.23–0.75,
p = 0.0024; Median FUP 7.1 yrs: p = 0.01) (2 studies
(Hoskin, 2007; Sathya, 2005), n = 312, low–high risk)
EBRT (low dose) ±HT: bPFS (10 yrs. p = 0.003/
p < 0.001; 10 yrs, HR 1.74, 95%-CI 1.48–2.04, 1 yr,
p < 0.0001; 10 yrs, p < 0.01), cPFS (10 yrs, p = 0.002/
p < 0.001; 10 yrs, HR 1.45, 95%-CI 1.03–2.06, 2 yrs;
p < 0.01; 10 yrs, distant metastases, p = 0.006) (4 studies
(Denham, 2008; Jones, 2011; Laverdie`re, 1997; Pilepich,
1995), n = 3357, low–high risk); OS (10 yrs, HR 0.60,
95%-CI 0.45–0.80; 7.6 yrs. HR 1.8, 95%-CI 1.1–2.9;
10 yrs, HR 0.63, 95%-CI 0.48–0.83; 10 years, HR 1.17,
95%-CI 1.01–1.35) (4 studies (Bolla, 2002; D’Amico,
2004; Denham, 2008; Jones, 2011). n = 3388, low–high
risk); DSS (10 yrs, HR 0.42, 95%-CI 0.33–0.55; 4.5 yrs,
p = 0.02; 10 yrs, HR 0.49, 95%-CI 0.32–0.74; 10 yrs, HR
1.87, 95%-CI 1.27–2.74; 10 yrs, p = 0.01; 15 yrs,
p = 0.008) (5 studies (Bolla, 2002; D’Amico, 2004;
Denham, 2008; Jones, 2011; Pilepich, 1995; Zagars,
1988). n = 3922, low–high risk)
EBRT (high dose): bPFS (Phoenix, HR 0.80, 95%-CI
0.64–0.97), mPFS (110 months, HR 0.79, 95%-CI 0.64–
0.97; 6 yrs, 64% vs. 70%, p = 0.03) (Peeters, 2006,
n = 664, low–high risk); cPFS (10 yrs, HR 0.57, 95%-CI
0.43–0.74) (Zietman, 2005, n = 393, low-intermediate
risk)
RP: mPFS (Time to ﬁrst event, p = 0.037) (Paulson,
1982, n = 90, low-intermediate risk)
EBRT (low
dose) + BT
EBRT (low dose): bPFS (Hoskin 2007, n = 218, low–
high risk); mPFS (HR 0.42, 95%-CI 0.23–0.75,
p = 0.0024; Median FUP 7.1 yrs: p = 0.01) (2 studies
(Hoskin, 2007; Sathya, 2005), n = 312, low–high risk)
EBRT (low dose): bPFS (n = 0 after mean FUP
22.7 months, PSA after 17.5 months: 0.68 ng/ml vs.
0.88 ng/ml, p = 0.44) (Zapatero-Ortuno, 2010, n = 30,
low-intermediate risk); OS (n = 0 after mean FUP
22.7 months; HR 1.36, 95%-CI 0.50–3.65, p = 0.54; 10
yrs, p = 0.2) (3 studies (Hoskin, 2007; Sathya, 2005;
Zapatero-Ortuno, 2010), n = 352, low–high risk)
(continued on next page)
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Table 2 (continued)
Intervention Relative eﬀect
Eﬀect greater than No signiﬁcant diﬀerence Eﬀect worse than
EBRT (low
dose) + HT
EBRT (low dose): bPFS (10 yrs. p = 0.003/p < 0.001;
10 yrs, HR 1.74, 95%-CI 1.48–2.04, 1 yr, p < 0.0001;
10 yrs, p < 0.01), cPFS (10 yrs, p = 0.002/p < 0.001;
10 yrs, HR 1.45, 95%-CI 1.03–2.06, 2 yrs; p < 0.01;
10 yrs, distant metastases, p = 0.006) (4 studies
(Denham, 2008; Jones, 2011; Laverdie`re, 1997; Pilepich,
1995), n = 3357, low–high risk); OS (10 yrs, HR 0.60,
95%-CI 0.45–0.80; 7.6 yrs. HR 1.8, 95%-CI 1.1–2.9;
10 yrs, HR 0.63, 95%-CI 0.48–0.83; 10 years, HR 1.17,
95%-CI 1.01–1.35) (4 studies (Bolla, 2002; D’Amico,
2004; Denham, 2008; Jones, 2011). n = 3388, low–high
risk); DSS (10 yrs, HR 0.42, 95%-CI 0.33–0.55; 4.5 yrs,
p = 0.02; 10 yrs, HR 0.49, 95%-CI 0.32–0.74; 10 yrs, HR
1.87, 95%-CI 1.27–2.74; 10 yr, p = 0.01; 15 yrs,
p = 0.008) (5 studies (Bolla, 2002; D’Amico, 2004;
Denham, 2008; Jones, 2011; Pilepich, 1995; Zagars,
1988). n = 3922, low–high risk)
EBRT (low dose): bPFS (2 yrs) (Laverdie`re, 1997,
n = 120, low–high risk); OS (10 yrs, 8.7 vs. 7.3 yrs,
p = 0.12; 15 yrs, no signiﬁcant diﬀerence) (2 studies
(Pilepich, 1995; Zagars, 1988), n = 534, low–high risk)
EBRT (low–high
dose)
EBRT (low–high dose) ± HT: bPFS (82.1 months, HR
0.71, 95%-CI 0.46–1.09) (Mok, 2012, n = 243,
intermediate risk)
EBRT (low–high
dose) + HT
EBRT (low–high dose): bPFS (82.1 months, HR 0.71,
95%-CI 0.46–1.09) (Mok, 2012, n = 243, intermediate
risk)
EBRT (high dose) EBRT (low dose): bPFS (Phoenix, HR 0.80, 95%-CI
0.64–0.97), mPFS (110 months, HR 0.79, 95%-CI 0.64–
0.97; 6 yrs, 64% vs. 70%, p = 0.03) (Peeters, 2006,
n = 664, low–high risk); cPFS (10 yrs, HR 0.57, 95%-CI
0.43–0.74) (Zietman, 2005, n = 393, low-intermediate
risk)
EBRT (low dose): cPFS (clinical failure, HR 0.89, 95%-
CI 0.69–1.15) (Peeters, 2006, n = 664, low–high risk);
DSS (54 months, p = 0.61; 110 months, HR 0.96, 95%-
CI 0.63–1.45) (2 studies (Beckendorf, 2004; Peeters,
2006), n = 968, low–high risk); bPFS (5 yrs, Phoenix,
23.5 vs. 32%; 10 yrs, Phoenix, p = p = 0.001) (2 studies
(Beckendorf, 2004; Zietman, 2005), n = 699, low–high
risk); OS (54 months, p = 0.52; 110 months, HR 0.99,
95%-CI 0.75–1.3; 8 yrs, no overall diﬀerence) (4 studies
(Beckendorf, 2004; Peeters, 2006; Pollack, 2000;
Zietman), n = 1662, low–high risk)
EBRT (low dose, HFRT) [vs. EBRT (high dose,
CFRT)]: bPFS (79% vs. 87%, p = 0.035) (Arcangeli,
2010, n = 114, intermediate-high risk)
EBRT (unclear
dose)
RP: bPFS (median time to failure: 55.5 vs. 56 months),
cPFS (median time to local progression: 65 vs.
64 months), DSS (3/70 vs. 1/67) (Stasi 2006, n = 137,
low–high risk)
EBRT (unclear
dose) + BT
EBRT (unclear dose)±BT ±HT: bPFS (60 months,
Phoenix, 83 vs. 90%, p = 0.4), cPFS (60 months, no
signiﬁcant diﬀerence for distal metastases and
locoregional control) (Garcı´a Blanco 2013, n = 62,
intermediate-high risk)
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EBRT (unclear
dose) + BT + HT
EBRT (unclear dose)±BT: bPFS (60 months, Phoenix,
83 vs. 90%, p = 0.4), cPFS (60 months, no signiﬁcant
diﬀerence for distal metastases and locoregional control)
(Garcı´a Blanco, 2013, n = 62, intermediate-high risk)
RP EBRT (low dose):mPFS (Time to ﬁrst event, p = 0.037)
(Paulson, 1982, n = 90, low-intermediate risk)
Watchful waiting: DSS (6 yrs: HR 0.50, 95%-CI 0.27–
0.91, p = 0.02) (Holmberg, 2002, n = 695, low-
intermediate risk); cPFS (local progression, 15 yrs: RR
0.34, 95%-CI 0.26–0.45; distant metastases: HR 0.63,
95%-CI 0.41–0.96, p = 0.03; bone metastases, HR 0.40,
95%-CI 0.22–0.70, p < 0.001) (2 studies (Wilt, 2012;
Holmberg, 2002), n = 1426, low–high risk)
Brachytherapy: bPFS (Giberti, 2009, n = 174, low-
intermediate risk) (Giberti, 2009, Crook, 2011), n = 208,
low-intermediate risk)
ERBT (unclear dose): bPFS (median time to failure:
55.5 vs. 56 months), cPFS (median time to local
progression: 65 vs. 64 months), DSS (3/70 vs. 1/67)
(Stasi 2006, n = 137, low–high risk)
RP ± EBRT: DSS (10 yr, 25/502 vs. 34/503) (Bolla,
2005, n = 1005, low–high risk); cPFS (10 yrs,
metastasis-free survival, p = 0.56) (Wiegel ,2009,
n = 307, intermediate-high risk) (2 studies (Bolla, 2005;
Thompson, 2006)), n = 532, low–high risk); OS (HR
1.18, 95%-CI 0.91–1.53; 10 yrs, p = 0.59) (2 studies
(Bolla, 2005; Wiegel, 2009), n = 1312, low–high risk)
Watchful waiting: OS (10 yrs: HR 0.88, 95%-CI 0.71–
1.08, p = 0.22; 6 yrs: p = 0.31) (3 studies (Madsen, 1988;
Wilt, 2012; Holmberg, 2002), n = 1568, low–high risk)
RP ± EBRT: cPFS (Median FUP 12 yrs: HR 0.71, 95%-
CI 0.54–0.94, p = 0.016), OS (Median follow-up 12 yrs:
HR 0.72, 95%-CI 0.55–0.96, p = 0.023) (Thompson,
2006, n = 425, intermediate-high risk); mPFS (10 yrs;
biochemical, chemical, death: HR 0.49 (95%-CI 0.41–
0.59), p = 0.001; 5 yrs: HR 0.53, 95%-CI 0.37–0.79,
p = 0.015) (2 studies (Bolla, 2005; Wiegel, 2009),
n = 1312, low–high risk); bPFS (10 yr, 105/502 vs. 238/
503; Median FUP 10.6 yrs: HR 0.62, 95%-CI 0.46–0.82,
p = 0.001; 10 yr, p < 0.01) (3 studies (Bolla, 2005;
Thompson, 2006; Wiegel, 2009), n = 1737, low–high
risk)
RP + EBRT RP: cPFS (Median FUP 12 yrs: HR 0.71, 95%-CI 0.54–
0.94, p = 0.016), OS (Median follow-up 12 yrs: HR 0.72,
95%-CI 0.55–0.96, p = 0.023) (Thompson 2006,
n = 425, intermediate-high risk); bPFS (10 yr, 105/502
vs. 238/503; Median FUP 10.6 yrs: HR 0.62, 95%-CI
0.46–0.82, p = 0.001) (2 studies (Bolla, 2005;
Thompson, 2006), n = 1430, low–high risk); mPFS (10
yrs; biochemical, chemical, death: HR 0.49 (95%-CI
0.41–0.59), p = 0.001; 5 yrs: HR 0.53, 95%-CI 0.37–0.79,
p = 0.015) (2 studies (Bolla, 2005; Wiegel, 2009),
n = 1312, low–high risk)
RP: DSS (10 yr, 25/502 vs. 34/503) (Bolla 2005,
n = 1005, low–high risk); OS (HR 1.18 (95%-CI 0.91–
1.53), p = p = 0.2024) (2 studies (Bolla, 2005, Wiegel,
2009), n = 1312, low–high risk)
Watchful waiting RP: DSS (10 yrs, HR 0.63, 95%-CI 0.36–1.09, p = 0.09)
(Wilt, 2012, n = 731, low–high risk); OS (10 yrs: HR
0.88, 95%-CI 0.71–1.08, p = 0.22; 6 yrs: p = 0.31)
(3 studies (Madsen, 1988; Wilt, 2012; Holmberg, 2002),
n = 1568, low–high risk)
RP: DSS (6 yrs: HR 0.50, 95%-CI 0.27–0.91, p = 0.02)
(Holmberg, 2002, n = 695, low-intermediate risk); cPFS
(local progression, 15 yrs: RR 0.34, 95%-CI 0.26–0.45;
distant metastases: HR 0.63, 95%-CI 0.41–0.96,
p = 0.03; bone metastases, HR 0.40, 95%-CI 0.22–0.70,
p < 0.001) (2 studies (Wilt, 2012; Holmberg, 2002),
n = 1426, low–high risk)
Reading advice: Outcome (follow-up, main ﬁnding) (number of studies, number of patients, D’Amico surrogate).
3DCR = Three-Dimensional Conformal Radiotherapy; bPFS = Biochemical progression-free survival; BT = Brachytherapy; CFRT = Conventionally fractionated radiotherapy; CI = Conﬁdence
interval; cPFS = Clinical progression-free survival; DSS = Disease-speciﬁc survival; EBRT = External Beam Radiotherapy; EORTC = European Organization for Research and Treatment of Cancer;
FUP = Follow-up; HDR = High-dose radiation; HFRT = Hypofractionated radiotherapy; HR = Hazard ratio; ml = Millilitre; mPFS = Mixed (biochemical and clinical) progression-free survival;
ng = Nanogram; OS = Overall survival; RD = Risk diﬀerence; RP = Radical Prostatectomy; RR = Relative risk; wk = Weeks; yrs = Year(s).
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Fig. 2. Network diagram showing all survival-related relative eﬀects. (Please note that a full version of this ﬁgure is available as an online
Appendix.)
2358 R.F. Wolﬀ et al. / European Journal of Cancer 51 (2015) 2345–2367in Fig. 3. Based on six studies, the pooled estimate for
comparison of EBRT (low dose) with EBRT (low
dose) + HT was RR 1.21 (95%-CI 1.12–1.30) in favour
of the combined treatment. Life expectancy for low to
high risk patients does appear to improve when HT is
added to low dose EBRT, however there is a suggestion
that this improvement may be at the cost of a loss of sex-
ual functioning (see information on D’Amico et al. [60]
in Table 2).
Where ‘head-to-head’ trials (i.e. A versus B) were not
identiﬁed, it was originally planned to perform indirect
comparisons. The RRs (with 95%-CIs) for A versus B
would have been estimated using ‘indirect’ methods
[13]. However, clinical diﬀerences in patient populations
prohibited indirect comparisons.3.4. Findings of the review
Based on an extensive search of the current literature,
36 relevant studies were identiﬁed, allowing twelve dif-
ferent pair-wise comparisons.
Findings from direct comparisons suggest that
EBRT, BT and RP are eﬀective treatments for localised
prostate cancer and that post-operative EBRT is also
eﬀective but might be associated with additional toxic-
ity; see Fig. 2 and Table 2.
Evidence from two smaller trials (n = 208), compar-
ing BT with RP in patients with low to intermediate risk
cancer suggest similar biochemical disease-free survivalwhen compared with RP, with favourable results for
BT in terms of sexual functioning [14–19]. The eﬀects
on urinary function are unclear. While one study reports
statistically signiﬁcant greater and more short-term uri-
nary problems, the other study suggests late changes
(after 5 years) in urinary function in favour of BT. Use
of BT in higher risk patients has not been evaluated in
any of the included RCTs.
In the light of the speciﬁc techniques employed in tri-
als, higher doses of EBRT result in favourable
survival-related outcomes (overall and progression-free
survival) but might be associated with more side eﬀects
(GI- and GU-toxicity), depending on technique.
Combining EBRT (low dose) with hormone therapy
showed statistically signiﬁcant advantages in terms of
overall survival (see Fig. 2 and Table 2).4. Discussion
In this systematic review, we aimed to assess the eﬃ-
cacy and adverse events associated with radiotherapy
(EBRT and/or BT) compared with other management
options in patients with prostate cancer.4.1. Comparison with other reviews
A number of recently published systematic reviews
assessed comparators identiﬁed and discussed here.
Most of these reviews did not identify any RCTs
Fig. 3. Forest plots for the endpoint ‘overall survival’.
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with the ﬁndings of this report, e.g. Cordeiro 2012
(HIFU) [20] and Dahabreh 2012 (active surveillance)
[21]. Stephenson et al. [22] aimed to “review the data
concerning the pros and cons of immediate or adjuvant
RT, or of an approach involving delayed or salvage RT
once BCR [biochemical recurrence] occurs”. They iden-
tiﬁed three RCTs also included in this review
[131,136,138]. A systematic review on low-dose-rate
brachytherapy for localised prostate cancer by
Peinemann et al. [23] included one randomised con-
trolled trial [19] also identiﬁed for this report.
Another systematic review included only
non-randomised studies [24]. Based on 140
non-randomised studies which assessed 11 diﬀerent
treatment types, Grimm et al. concluded that “in terms
of biochemical-free progression, brachytherapy provides
superior outcome in patients with low-risk disease”.
This conclusion is broadly in line with the ﬁndings of
our review of randomised controlled trials where the
study by Giberti et al. [19] including 174 patients showed
no signiﬁcant diﬀerence of biochemical progression-freesurvival between BT and RP. However, the RCT
showed a statistically signiﬁcant advantage of
brachytherapy regarding patient satisfaction and
self-reported sexual functioning (see Fig. 2 and Table 2).
4.2. Strengths, limitations, uncertainties
The systematic review process followed published
guidelines [9,10]. In order to try to identify all poten-
tially relevant evidence relating to the review question
as well as to reduce the risk of publication bias, an
extensive range of resources was searched. In addition,
reference lists of included studies were checked to iden-
tify further relevant studies. Published and unpublished
trials (such as conference abstracts) irrespective of size
or follow up period were eligible for inclusion.
However, the size and duration of trials was considered
when appraising the evidence.
Although this review sought wherever possible to
reduce the risk of bias during the review processes and
analyses, the ﬁndings may still be subject to certain lim-
itations and uncertainties beyond our control. One such
2360 R.F. Wolﬀ et al. / European Journal of Cancer 51 (2015) 2345–2367factor would be the small size of trials which means that
important eﬀects, or non-eﬀects cannot necessarily be
detected because of underpowering.
The reliability of the ﬁndings might be further limited
by methodological or reporting weaknesses of the
included studies. Results of four studies were only
reported in abstracts, which made it diﬃcult to assess
the risk of bias and hence comment on the reliability
of the ﬁndings. Our inclusion criteria are designed to
be comprehensive so that no study of potential value
is missed. However, this inevitably means that some
studies will be included which provide very little evi-
dence of direct use but future researchers can be conﬁ-
dent that nothing has been overlooked.
Matching of patients to treatment is facilitated by
stratifying patients into risk groups. There is currently
a debate as to how patients should be stratiﬁed accord-
ing to risk factors [25]. In this systematic review, the
D’Amico risk group classiﬁcation was used [12] because
it was most prevalent within the literature although we
are aware that other systems have been used, e.g. the
system of the National Comprehensive Cancer
Network (NCCN) [26].
However, there was considerable variation in the way
eligible populations were described and deﬁnitions of
patient characteristics were sometimes imprecise, mean-
ing that patients could only be described as having “low
to high risk” disease.
We have sought to report on evidence which has
already been reported. We are aware that many ongoing
studies (e.g. the Prostate Testing for Cancer and
Treatment (ProtecT) trial) oﬀer potential to consider-
ably increase the knowledge pool. Keeping abreast of
emerging research is a challenge faced by all systematic
reviews.
4.3. Implications and recommendations for further
research
Further large, methodologically robust randomised
controlled trials are needed. These need to be compliant
with established reporting standards, use relevant out-
come measures collected over long follow-up periods
and report data in a form that can be extracted and
incorporated into databases and meta-analyses.
It should be noted that such trials are logistically very
diﬃcult to complete due to funding issues and patient
and physician preferences. However, this review identi-
ﬁed ten ongoing studies which might be able to ﬁll gaps
in the current evidence base, thereby demonstrating that
RCTs are actively being conducted in this area but it
should be noted that this list might not be complete
[27–40]. The ProtecT trial will help in this regard and
should inform which of radiotherapy, radical prostatec-
tomy and active surveillance should be used in daily clin-
ical practice [40].5. Conclusions
Evidence from this systematic review suggest that,
when used appropriately, external beam radiotherapy,
brachytherapy and radical prostatectomy can result in
improved overall survival, progression-free survival as
well as functioning (urinary/bowel/sexual) in localised
disease. All treatments have their unique adverse events
proﬁles.
Our ability to make ﬁrm recommendations for speci-
ﬁc risk-stratiﬁed sub-groups or variants of main tech-
nologies is limited by the way these issues have been
described in the literature. This review provides infor-
mation as to how such issues might be addressed in
future studies.
Further large, methodologically robust, randomised
controlled trials are needed to report treatment-speciﬁc
and treatment combination-speciﬁc outcomes in deﬁned
prostate cancer risk groups. These will provide the evi-
dence base for the relatively newer therapies, e.g.
HIFU, help reinforce current consensus guidelines,
establish greater standardisation across practices and
point the way towards research gaps.
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Appendix 1. Search strategy for MEDLINE
Medline (OvidSP): 1946-2014/Feb week 4, searched
26/02/2014
(1) ((Prostate or prostatic) adj3 (carcinoma$ or can-
cer$ or neoplas$ or tumo?r$ or malignan$ or ade-
nocarcinoma$ or adenoma$)).ti,ab,ot. (87042)
(2) Prostatic Neoplasms/(89475)
(3) or/1–2 (104337)
(4) randomised controlled trial.pt. (362550)
R.F. Wolﬀ et al. / European Journal of Cancer 51 (2015) 2345–2367 2361(5) controlled clinical trial.pt. (87486)
(6) randomised.ab. (262961)
(7) placebo.ab. (142353)
(8) clinical trials as topic.sh. (167729)
(9) randomly.ab. (187682)
(10) trial.ti. (112719)
(11) or/4–10 (834503)
(12) 3 and 11 (8161)
(13) exp animals/not humans.sh. (3880944)
(14) 12 not 13 (8077)
(15) (201303$ or 201304$ or 201305$ or 201306$ or
201307$ or 201308$ or 201309$ or 20131$ or
2014$).ed,dc. or (2013$ or 2014$).yr. (742841)
(16) 14 and 15 (590)*
Trials ﬁlter (best sensitivity and speciﬁcity) from:
Lefebvre C, Manheimer E, Glanville J. Chapter 6:
searching for studies. Box 6.4.c: Cochrane Highly sensi-
tive search strategy for identifying randomised con-
trolled trials in Medline 2008 version; OVID format.
In: Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Interventions
Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration, 2011. Available from www.cochrane-
handbook.org.
*This search updated a previous search. Therefore the
number of references does not match the number
reported in the ﬂow chart.Appendix 2. Supplementary data
Supplementary data associated with this article can
be found, in the online version, at http://dx.doi.org/10.
1016/j.ejca.2015.07.019.
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